[Guest Post] Of Snakes and Artistic Value: Bologna IP Court Slithers Through Design, Shape Marks and Copyrights in a post-Cofemel landscape [Guest Post] Of Snakes and Artistic Value: Bologna IP Court Slithers Through Design, Shape Marks and Copyrights in a post-Cofemel landscape Reviewed by Marcel Pemsel on Thursday, March 05, 2026 Rating: 5
BREAKING: Imminent new referral to the EBA on the relevance of G1/24 to added matter BREAKING: Imminent new referral to the EBA on the relevance of G1/24 to added matter Reviewed by Dr Rose Hughes on Tuesday, March 03, 2026 Rating: 5
[Guest post] A tale of David and Goliath in Gangnam style? [Guest post] A tale of David and Goliath in Gangnam style? Reviewed by Eleonora Rosati on Tuesday, March 03, 2026 Rating: 5
[Guest Post] UK Assessment of Computer Implemented Inventions moves closer to EPO Practice - but by how far? (Emotional perception [2026] UKSC 3) [Guest Post] UK Assessment of Computer Implemented Inventions moves closer to EPO Practice - but by how far? (Emotional perception [2026] UKSC 3) Reviewed by Dr Rose Hughes on Tuesday, March 03, 2026 Rating: 5
Vow Renewal in Silicon Valley? What the Microsoft-OpenAI Partnership Really Secures Vow Renewal in Silicon Valley? What the Microsoft-OpenAI Partnership Really Secures Reviewed by Georgia Jenkins on Tuesday, March 03, 2026 Rating: 5
Otsuka seeks to appeal decision to deny PTEs for formulation patents in Australia Otsuka seeks to appeal decision to deny PTEs for formulation patents in Australia Reviewed by Dr Claire Gregg on Monday, March 02, 2026 Rating: 5
High Court of Australia refuses special leave in Aristocrat: what this means for computer-implemented inventions High Court of Australia refuses special leave in Aristocrat: what this means for computer-implemented inventions Reviewed by Dr Claire Gregg on Sunday, March 01, 2026 Rating: 5
Description amendments can extend protection (T 439/22) Description amendments can extend protection (T 439/22) Reviewed by Dr Rose Hughes on Saturday, February 28, 2026 Rating: 5
The validity and value of cell therapy safety protocol inventions (T 1555/23) The validity and value of cell therapy safety protocol inventions (T 1555/23) Reviewed by Dr Rose Hughes on Friday, February 27, 2026 Rating: 5
Never Too Late: If you missed the IPKat last week! Never Too Late: If you missed the IPKat last week! Reviewed by Wissam Bentazar on Friday, February 27, 2026 Rating: 5
Powered by Blogger.